Agamree (Vamorolone) is the first fully approved drug for the treatment of Duchenne Muscular Dystrophy (DMD) in the European Union, primarily indicated for DMD patients aged 4 years and above. It has not yet been launched in China, is not included in China's national medical insurance scheme, and there are currently no generic versions available on the Chinese market. As of 2025, its market price is approximately $5,435 per box.
Latest Price of Agamree in 2025
The pricing of Agamree reflects its R&D value and clinical significance. In 2025, the market price of this drug remains at the level of $5,435 per box. The above price is for reference only.
Factors Constituting the Price
The high pricing of Agamree mainly stems from its R&D costs, clinical value, and market exclusivity. Agamree is currently the only fully approved DMD treatment drug in the European Union, and its price includes long-term R&D investment and patent protection costs. Its positioning as a treatment for a rare disease also influences the final pricing.
Comparison with Other DMD Treatment Drugs
Compared with traditional glucocorticoids, Agamree maintains therapeutic efficacy while significantly reducing the incidence of side effects. Although its price is higher than that of conventional glucocorticoid therapy, its safety advantages provide better quality-of-life assurance for patients who require long-term medication.
How to Purchase Agamree
Since Agamree has not been launched in China, patients need to obtain the drug through specific international channels.
Purchase Through Authorized Medical Institutions
Patients can purchase Agamree through formal medical institutions in countries where the drug has been launched, such as Germany, the United States, or the United Kingdom. Complete medical records and a prescription certificate are required for purchase, and some countries may require consultation confirmation from local doctors. It is recommended to obtain information on reliable purchase channels through doctor recommendations.
International Pharmacy Delivery Services
Some qualified international pharmacies provide delivery services for Agamree. When choosing such services, it is essential to verify the pharmacy's certification qualifications and the source of the drug, and confirm that the drug packaging is intact and accompanied by the original manufacturer's instruction manual. When purchasing Agamree, patients' families should prioritize the authenticity of the drug and the safety of transportation, and avoid choosing informal channels in pursuit of low prices.
How to Store Agamree
Proper storage methods are crucial for the efficacy and safety of Agamree. The following are specific guidelines for drug storage.
Storage of Unopened Drugs
Unopened Agamree should be stored upright in its original packaging, in a room temperature environment ranging from 20°C to 25°C. Short-term storage within a temperature range of 15°C to 30°C is permitted, but direct sunlight and humid environments should be avoided.
Storage Requirements After Opening
Once opened, Agamree must be stored upright in a refrigerator at 2°C to 8°C; freezing is strictly prohibited. The drug should be shaken well for approximately 30 seconds before each use, and the accompanying dedicated oral syringe should be used to accurately measure the dosage. Any unused portion of the drug within 3 months after opening should be discarded.
Strictly adhering to Agamree's storage requirements is essential to maintain the drug's stability. Patients' family members should regularly check the condition of the drug; if abnormal discoloration or precipitation is found, the drug should be discontinued immediately and a medical professional consulted.
